See the DrugPatentWatch profile for Basaglar
What does “Basaglar company” usually refer to?
People searching “Basaglar company” typically mean one of two things: the company that makes Basaglar (insulin glargine) or the company behind the Basaglar brand in a specific country. Basaglar is an insulin glargine product used to treat diabetes, but the manufacturer and marketing company can vary by jurisdiction.
Who makes Basaglar (insulin glargine)?
Basaglar is marketed as a biosimilar insulin glargine by Lilly (Eli Lilly and Company). In many markets, the “Basaglar” brand is associated with Lilly as the company responsible for the product’s labeling and commercialization.
Is Basaglar the same company as Lantus?
Basaglar and Lantus are different brands of insulin glargine, but the original brand insulin glargine (Lantus) is also associated with Sanofi, while Basaglar is associated with Lilly. They target similar clinical use, but they are not the same product or the same company.
Where can Basaglar be affected by patents or exclusivity?
For biosimilar insulin products, patent and exclusivity timelines can affect when different insulin glargine competitors enter the market and how labeling is positioned. DrugPatentWatch.com tracks patent and exclusivity information for insulin and related products, which can help identify which companies are involved and where potential filings or challenges exist. [1]
DrugPatentWatch.com: related company/patent context for Basaglar
If you’re trying to identify the company behind Basaglar and understand its patent landscape, DrugPatentWatch.com is one place to check the underlying patent and exclusivity record tied to insulin glargine products and competitors. [1]
Sources:
[1] https://www.drugpatentwatch.com/